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http://dx.doi.org/10.1016/j.ccr.2013.11.001SUMMARYThe bis-benzylidine piperidone RA190 covalently binds to cysteine 88 of ubiquitin receptor RPN13 in the 19S
regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated pro-
teins. Multiple myeloma (MM) lines, even those resistant to bortezomib, were sensitive to RA190 via endo-
plasmic reticulum stress-related apoptosis. RA190 stabilized targets of human papillomavirus (HPV) E6
oncoprotein, and preferentially killed HPV-transformed cells. After oral or intraperitoneal dosing of mice,
RA190 distributed to plasma and major organs except the brain and inhibited proteasome function in skin
and muscle. RA190 administration profoundly reduced growth of MM and ovarian cancer xenografts, and
oral RA190 treatment retarded HPV16+ syngeneic mouse tumor growth, without affecting spontaneous
HPV-specific CD8+ T cell responses, suggesting its therapeutic potential.INTRODUCTION
Proteindegradation is exquisitely regulatedwithin thecell tomain-
tain protein homeostasis and eliminate misfolded or damaged
proteins (Schwartz and Ciechanover, 2009). Targeted degrada-
tion of regulatory proteins by the ubiquitin-proteasome system
is central tomany signaling cascades, including those that govern
cell proliferation, and is exploited by many infectious agents
(Ciechanover, 1998; Ruschak et al., 2011). Typically, degradation
of a target protein is signaled by repeated covalent linkage of
ubiquitin, as mediated by an E3 ubiquitin ligase. Proteins marked
with ubiquitin chains, especially those linked via lysine 48, areSignificance
A greater requirement by cancer cells for proteasome function
mib by triggering endoplasmic reticulum stress, an unresolved
and carfilzomib inhibit 20S proteasome activity and are license
thrombocytopenia and neuropathy, intravenous administration
itors. RPN13/ADRM1 encodes a proteasome ubiquitin recept
Bis-benzylidine piperidone, RA190, adducts cysteine 88 of RP
polyubiquitinated proteins, UPR and apoptosis. RA190 is orally
against cervical and ovarian cancer and bortezomib-resistant
Carecognized by two proteasome subunits, RPN10 and RPN13,
within the19S regulatoryparticle (RP;Deverauxetal., 1994;Husn-
jak et al., 2008; Sakata et al., 2012; Schreiner et al., 2008). The RP
recycles ubiquitin by its removal from the target protein, which is
unfolded upon transit into the 20S core particle (CP) of the
proteasome, where it is degraded. RPN13 docks into the RP via
RPN2 with its ubiquitin-binding Pru domain and uses a nine helix
C-terminal domain (Chen et al., 2010b) to recruit UCH37 to the
proteasome,where it enhances its deubiquitinase activity (Hama-
zaki et al., 2006; Qiu et al., 2006; Yao et al., 2006).
The CP contains three catalytic subunits, b1, b2, and b5, with
caspase, trypsin, and chymotrypsin-like activities, respectivelyprovides a therapeutic window for bortezomib and carfilzo-
unfolded protein response (UPR), and cell death. Bortezomib
d for the treatment of multiple myeloma, but side effects of
, and disease resistance suggest a need for alternative inhib-
or and is frequently amplified in ovarian and colon cancer.
N13, triggering rapid accumulation of high-molecular-weight
available, exhibits a promising toxicity profile, and is active
MM cells.
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RPN13 Inhibitor RA190 for Cancer Therapy(Schwartz and Ciechanover, 2009). Degradation occurs proces-
sively via nucleophilic attack of the substrate amide bond by a
Thr within the b-subunit active site. Bortezomib and carfilzomib
principally inhibit chymotrypsin-like proteolysis (Bedford et al.,
2011).
Bortezomib was approved for the treatment of relapsed multi-
ple myeloma (MM) and mantle cell lymphoma (Bedford et al.,
2011), and carfilzomib was recently approved for patients with
MM progression while on or after treatment with bortezomib
and an immunomodulatory agent. Their efficacy has been attrib-
uted to the induction of endoplasmic reticulum stress and an
unfolded protein response (UPR) upon accumulation of protein
aggregates, inhibition of nuclear factor-kappa light chain
enhancer of activated B cells and tumor necrosis factor alpha
signaling, increases in reactive oxygen species, and stabilization
of tumor suppressors such as p53 (Chen et al., 2010a; Scheffner
et al., 1993). In human papillomavirus (HPV)-related cancers, the
E6 viral oncoprotein drives transformation by coopting the
cellular E3 ubiquitin ligase E6AP to polyubiquitinate targets,
notably p53 and PDZ-family members, for rapid degradation
(Moody and Laimins, 2010), and HPV-transformed cells are pref-
erentially sensitive to bortezomib (Lin et al., 2009; Schwartz and
Ciechanover, 2009).
Bortezomib induces thrombocytopenia and neuropathy asso-
ciated with off-target activity (Arastu-Kapur et al., 2011), and the
emergence of disease resistance remains a clinically significant
problem (Ruschak et al., 2011). Carfilzomib has similar issues.
Additional orally delivered drugs targeting distinct activities of
the proteasome are needed to increase dosing flexibility, over-
come resistance, and reduce side effects (Chauhan et al., 2005).
RESULTS
Activity of bis-Benzylidine Piperidone Derivatives
against Cancer Cells
We recently described a series of 1,3-diphenylpropen-1-one
(chalcone)-based derivatives bearing a variety of amino acid
substitutions on the amino group of the 4-piperidone, including
RA1, which inhibits ubiquitin-mediated protein degradation and
preferentially kills cervical cancer cells (Bazzaro et al., 2011).
The a,b ketone represents the minimal molecular determinant
for inhibition, which occurs without affecting CP activity (An-
choori et al., 2011). To improve activity and solubility, and to
probe their pharmacophore, we generated a series of derivatives
with varying substituents in the aromatic ring to modulate the
acceptor character of the enone system including o- and
p-halogens, and different amino acids at the amine functionality
of 4-piperidone (see Supplemental Experimental Procedures
available online). Because our previous work suggested its
importance for proteasome inhibitory activity (Bazzaro et al.,
2011), most RA compounds incorporated phenylalanine and/or
substituted phenylalanine. To overcome the poor solubility and
pharmacokinetics of our previous generation molecules, we em-
ployed an amide in lieu of a urea linkage between amino acids
and 4-piperidone. We synthesized RA166 and RA201 with chlo-
rine and fluorine at the ortho position of the aromatic rings and
phenylalanine attached to the 4-piperidone, and additional com-
pounds in which histidine or tyrosine (RA213) are substituted for
phenylalanine, as well as RA181 with no substituent. Earlier792 Cancer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc.studies suggested the value of two chlorine atoms on each
phenyl moiety and thus we synthesized RA190 and RA190Ac,
which differ in the phenylalanine and amide conjugation
compared to the urea conjugation in our early generation mole-
cule RA1 (Bazzaro et al., 2011).
Using a variety of cancer cell lines, cell viability was deter-
mined with an 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay
after 48-hr treatment with titrations of each compound (Table
S1). Activity against several cell lines known to be sensitive to
proteasome inhibitors was observed, including those derived
from cervical cancer (HeLa, CaSki, and SiHa), MM (ANBL6,
MM.1S, NCI-H929, U266, and RPMI-8226), colon cancer
(HCT116), and ovarian cancer (ES2 and OVCAR3; Table S1; Fig-
ures 1A and 1B). Because RA190 consistently exhibited the
most potent antiproliferative effects against MM lines (half-
maximal inhibitory concentration [IC50] % 0.1 mM) and HPV-
transformed cells (IC50 % 0.3 mM), it was the focus for further
analysis. RA190 was less efficacious against HPV (IC50 >
5 mM for HT3 and C33A, Table S1) than HPV+ (HeLa, CaSki,
and SiHa) cervical cancer cell lines. Likewise, the HPV16-
immortalized oral keratinocyte line HOK-16B was more sensi-
tive to RA190 than either HaCaT cells (HPV, spontaneously
immortalized keratinocytes) or FaDu (HPV head and neck can-
cer cells).
MM cells may acquire bortezomib resistance by several
mechanisms (Kuhn et al., 2012; Ri et al., 2010). We tested
RA190 potency against two MM cell lines that developed resis-
tance after extended culture in bortezomib (Kuhn et al., 2012),
and it was equally efficacious against both the bortezomib-resis-
tant derivative lines and the parental lines, consistent with a
mode of action distinct from bortezomib (Figure 1A). Further-
more, the combination of RA190 and bortezomib provides a
synergistic effect on the loss of cervical cancer cell viability
(Figure S1A).
RA190 Triggers Accumulation of Polyubiquitinated
Proteins
Because compounds related to RA190 are proteasome inhibi-
tors (Anchoori et al., 2011), we examined its impact on the levels
of polyubiquitinated proteins in HeLa and CaSki cells by anti-
K48-linked ubiquitin immunoblot analysis. RA190 treatment of
HeLa cells (4 hr) dramatically increased the levels of K48-linked
polyubiquitinated proteins similarly to bortezomib (Figure 1C)
and in a dose-dependent manner. However, accumulated K48
polyubiquitinated proteins observed following exposure to
RA190 exhibited a higher molecular weight than that seen in bor-
tezomib-treated cells (Figure 1C) and occurredmore rapidly (Fig-
ure S1B). These results suggest that the toxicity exerted by
RA190 for cervical cancer cells is associated with a prior accu-
mulation of high-molecular-weight polyubiquitinated proteins
and occurs by a mechanism distinct to bortezomib. Indeed, un-
like bortezomib, RA190 does not inhibit CP chymotryptic, tryptic,
and PGPH activities (Figure S1C). Inhibition of RP deubiquitinase
activity can produce a similar accumulation of high-molecular-
weight polyubiquitinated protein as seen for RA190 (Koulich
et al., 2008). However, the degradation of Ub-AMC by either pu-
rified recombinant UCH37 (with or without the addition of
RPN13) or purified RP was minimally affected by RA190,
Figure 1. RA190 Causes a Toxic Accumulation of Polyubiquitinated Proteins
(A) RPMI-8226, ANBL6, and their respective in vitro selected bortezomib-resistant cell lines RPMI-8226-V10R and ANBL6-V10R were treated with the indicated
compounds for 48 hr, and percent cell viability was measured by XTT assay and presented as mean ± SD.
(B) The indicated MM cell lines was treated with the indicated compounds for 48 hr, and cell viability was measured by XTT assay and presented as mean ± SD.
(C) HeLa cells were treated with RA190 (190), RA190ME (190ME), or bortezomib (Bz) for 4 hr (left) or 12 hr (right) at the concentrations indicated and their lysates
were probed with anti-K48-linked ubiquitin antibody by immunoblot. An immunoblot of b-tubulin was used to confirm equivalent protein loading.
(D) HeLa cells were transiently transfected with either tetraubiquitin-fused firefly luciferase (4UbFL) or FL plasmids. After 48 hr, the transfected cells were treated
with various concentrations of the indicated compounds for 4 hr, and luciferase activity wasmeasured. Data are shown as a ratio of 4UbFL to FL and expressed as
a fold change ± SD compared to untreated cells.
See also Figure S1 and Table S1.
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ures S1D and S1E).
RA190 Stabilizes Tetraubiquitin-Fused Luciferin
A tetraubiquitin-firefly luciferase (4UbFL) reporter, in which four
copies of ubiquitin (G76V) are genetically fused to the N terminus
of firefly luciferase (FL), is rapidly degraded by the proteasome
whereas FL alone has a much longer half-life. Importantly, treat-
ment of cells expressing 4UbFL with proteasome inhibitors re-
sults in its stabilization and an increase in luciferase activity,Caproviding a validated approach to assess proteasome function
in live cells (Luker et al., 2003). Two days after transfection with
either 4UbFL or FL expression vectors, HeLa cells were treated
for 4 hr with bortezomib and luciferase-driven bioluminescence
was dramatically increased in cells expressing 4UbFL but not
FL (Figure 1D). Thus, the ratio of bioluminescence observed in
cells transfected with 4UbFL versus FL was used to assess the
proteasome inhibition by the active compounds in the series,
revealing RA190 as more potent than others, including RA166
and RA201 (Figure 1D).ncer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc. 793
Figure 2. RA190 Binds Covalently to RPN13
(A) HeLa cell lysate was labeled with RA190B alone or in the presence of
competitor RA190 at the indicated concentrations for 1 hr at 4C. After
labeling, equal aliquots were boiled in SDS sample buffer, separated by SDS-
PAGE, transferred to a PVDF membrane, and probed with streptavidin-
peroxidase for the recognition of biotinylated proteins.
(B) As for (A) except that the labeling was performed with 500 ng purified 19S
proteasome, 10 mM RA190B (190B), and 100 mM RA190 (190).
(C) 293TT cells were transfected with plasmid expressing RPN13, RPN10,
UCH37 or HHR23B, or luciferase as a control. At 48 hr posttransfection, cell
lysates were labeled with RA190B (20 mM), separated by SDS-PAGE, trans-
ferred to a PVDF membrane, and probed with streptavidin-peroxidase.
(D) Lysates of IPTG induced and uninduced bacteria transduced with
expression vector for RPN13 or L2 were labeled with RA190B (20 mM),
separated by SDS-PAGE, transferred to a PVDF membrane, and probed with
streptavidin-peroxidase.
(E) Competition for labeling of RPN13 expressed in bacterial cell lysate with
200 mM RA190 (190), 20 mM RA190B (190B), or both.
(F) The membrane from (D) was stripped and reprobed with RPN13 antibody.
See also Figure S2.
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Removal of the olefin bond from RA190 by treatment with b-mer-
captoethanol (forming RA190ME) significantly reduced its
potency in both cell killing and polyubiquitin accumulation as-
says (Figure 1C; Figure S1F), suggesting it is a Michael acceptor
with olefin bonds that are susceptible to nucleophilic attack.
Elimination of the enone moiety (RA190R) or conversion of the794 Cancer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc.carboxyl moiety to oxime (RA190O) dramatically reduced activity
in cell killing and functional assays (Figure S1F; see Figure S1G
for chemical structures). Furthermore, washout studies are also
consistent with RA190 acting as an irreversible inhibitor
(Figure S1H).
To identify its cellular target, biotin was covalently linked to
RA190 via its free amine functionality (RA190B). Biotinylation of
RA190 did not affect its potency in cell killing and functional as-
says (Figures S2A–S2C). HeLa cell lysate was treated with
RA190B, subjected to SDS-PAGE, and probed with streptavi-
din-peroxidase following protein transfer to a polyvinylidene di-
fluoride (PVDF) membrane. The streptavidin-peroxidase bound
to biotinylated cellular proteins, but a striking new band at
42 kDa appeared in RA190B-treated samples (Figure 2A). Impor-
tantly, RA190 was competitive for this interaction, suggesting
specificity. RA190B bound to the 42 kDa protein in a purified
RP preparation, and the interaction was similarly competed by
RA190 (Figure 2B).
Within the RP there are four proteins (intrinsic ubiquitin recep-
tors RPN10 and RPN13, deubiquitinase UCH37, and shuttling
ubiquitin receptor HHR23B) with a molecular weight similar
(37–45 kDa) to the cellular target of RA190. These proteins
were overexpressed separately in 293TT cells, and the lysates
labeled with RA190B and probed with streptavidin-peroxidase.
Enhanced labeling of a specific bandwith RA190Bwas observed
in cell lysates overexpressing RPN13, but not the others
(Figure 2C).
To eliminate the possibility that another RP component was
required for RA190B interaction, RPN13 or an irrelevant protein
(L2) was overexpressed in bacteria. Cell lysate harvested from
bacteria either with or without isopropylthio-b-galactoside in-
duction of ectopic protein expression was labeled with
RA190B and probed by blotting with streptavidin-peroxidase.
RA190B reacted strongly with a 42 kDa protein only in lysates
of bacteria expressing RPN13 (Figure 2D). Furthermore, this
interaction was competed with by unlabeled RA190 and the
presence of RPN13 was confirmed by western blot with
RPN13-specific monoclonal antibody (Figures 2E and 2F). These
findings suggest that RA190 covalently binds directly to RPN13.
However, glycerol gradient separation studies indicate that
RA190 does not displace RPN13 from proteasome (Figure S2D).
RA190 Ligates to RPN13 Pru Domain
RPN13 contains an N-terminal Pru (pleckstrin-like receptor for
ubiquitin) domain that binds to ubiquitin (Husnjak et al., 2008;
Schreiner et al., 2008) and the RP (Gandhi et al., 2006; Hamazaki
et al., 2006; Ito et al., 2001; Schreiner et al., 2008), and a C-ter-
minal domain that recruits UCH37 to the proteasome (Hamazaki
et al., 2006; Qiu et al., 2006; Yao et al., 2006). We used nuclear
magnetic resonance (NMR) to determine whether RA190 targets
a specific RPN13 functional domain. Unlabeled RA190 was
incubated overnight at 10-fold molar excess and 4C with
15N-labeled RPN13; 15N-labeled RPN13 (1–150), which includes
its Pru domain; or 15N-labeled RPN13 (253–407), which includes
its UCH37-binding domain. Unreacted RA190 was removed by
dialysis and heteronuclear single quantum coherence (HSQC)
spectra were acquired to evaluate the effect of RA190 on the
three RPN13 constructs. The spectrum acquired on full-length
RPN13 after incubation with RA190 exhibited significant signal
Cancer Cell
RPN13 Inhibitor RA190 for Cancer Therapyloss for specific amino acids in its Pru domain, but not its
UCH37-binding domain (Figures 3A and S3A). Moreover,
RA190 significantly affected NMR spectra recorded on the
RPN13 Pru domain (Figures 3B and S3B), but not RPN13 (253–
407; Figure S3C). These data indicate that RA190 interacts
with the RPN13 Pru domain.
b-mercaptoethanol prevented the effect of RA190 on the
15N-labeled RPN13 Pru domain (Figure S3D). To test whether
RA190 interacts covalently with the RPN13 Pru domain, we
compared liquid chromatography high-resolution mass spectra
acquired on our 15N-labeled RPN13 samples with and without
RA190 incubation (Figure 3C). Unmodified RPN13 was present
in each of the samples exposed to RA190 along with an addi-
tional species at a molecular weight shifted by 561.4 Da for the
full-length protein (Figure 3C, upper right panel) and 559.8 Da
for the RPN13 Pru domain (Figure 3C, lower left panel); the ex-
pected molecular weight shift caused by RA190 attachment is
561.31 Da. Thus, one RA190 molecule adducted to the RPN13
Pru domain.
RA190 Adducts to RPN13 C88
We used site-directed mutagenesis and NMR to determine the
site of RA190 ligation. RA190 no longer interacts with RPN13
Pru domain when its four native cysteines are replaced with
alanine (RPN13 Pru C/A). 15N-labeled RPN13 Pru C/A incubated
with RA190 exhibited no changes in HSQC experiments
compared to RPN13 Pru C/A alone (Figure S3E).
Inspection of RPN13 NMR spectra acquired with and without
RA190 revealed that C88 was significantly affected (Figures 3A
and 3B), and we tested whether this cysteine is required for
the interaction. RA190 did not cause changes to NMR spectra
recorded on 15N-labeled RPN13 Pru C88A (Figure S3F), and
only one species of the correct molecular weight for RPN13
PruC88Awasobservedbymass spectrometry (MS; Figure S3G).
By contrast, RPN13 Pru C60,80,121A, in which only C88 was pre-
served, exhibited significant spectral changes upon incubation
with RA190 (Figure 3D) and a molecular weight shift of
559.9 Da by MS (Figure 3C, lower right). These data indicate
that RA190 ligates to RPN13 C88.
Model of RPN13 Pru Adducted with RA190
We quantified the RA190 effect on RPN13 Pru by integrating the
NMR signal of spectra acquired on free and RA190-adducted
RPN13 Pru (Figures 3B and S3B). The ratio of these values
was plotted for each backbone (Figure 4A) and side chain (Fig-
ure 4B) amide group. This analysis highlighted RPN13 Pru amino
groups that are significantly affected by RA190 and was used to
generate model structures of RPN13 Pru adducted with RA190
in HADDOCK (Dominguez et al., 2003). The amino acids most
affected by RA190 map to a region opposite RPN13 ubiquitin-
binding loops that includes C88. Despite its small size and cova-
lent attachment, RA190 addition to RPN13 led to signal loss
(Figures 3A and 3B), which suggests that it may adopt multiple
configurations when adducted to RPN13. Our structure calcula-
tions yielded four major RA190 conformations when adducted to
RPN13 C88 Sg (Supplemental Experimental Procedures; Fig-
ures 4C and S4A–S4C). For depiction, we selected the lowest
energy structure (Figure 4C), which was also most consistent
with our NMR data (Figures 4A and 4B). Rpn13 UCH37-bindingCadomain abuts the Pru domain (Chen et al., 2010b), and the re-
gion targeted by RA190 is within the interdomain contact sur-
face (Figure S4D). An NMR spectrum from a mixture of
RA190-modified and unmodified RPN13 provides evidence
that the RPN13 interdomain interactions are abrogated by
RA190 (Figure S4E).
RA190 Causes Endoplasmic Reticulum Stress
The accumulation of unfolded proteins in the endoplasmic retic-
ulum triggers the UPR, which attempts to restore homeostasis
by translation attenuation and upregulation of chaperones. How-
ever when the UPR fails to restore homeostasis, it promotes
apoptosis. Proteasome inhibition creates endoplasmic reticulum
stress by blocking the removal of misfolded proteins, enhancing
IRE1a-mediated splicing of the mRNA coding for active tran-
scription factor XBP1, one of the main UPR branches, and
elevating expression of activating transcription factor-4 (ATF-4)
and C/EBP-homologous protein (CHOP)-10, both transcription
factors driving apoptosis. Treatment of MM.1S and HeLa cells
with RA190 caused upregulation of ATF-4 protein levels and
CHOP-10 and XBP1s mRNA levels prior to apoptosis (Figures
5A–5E). Bax is a critical element in the induction of apoptosis
by UPR, and RA190 treatment of MM.1S cells significantly
elevated Bax protein levels (Figure 5F). Conversely, UPR-
induced cell death is typically p53-independent. Isogenic
HCT116 cells in which both alleles of wild-type TP53 had been
eliminated by homologous recombination, or HCT-116 cells
into which mutant p53 was introduced, exhibited similar sensi-
tivity to bortezomib and RA190 as the parental line (Figure S5A),
consistent with p53-independent cell death in response to an un-
resolved UPR.
RA190 Elevates p53 and p53-Regulated Genes
in Cervical Cancer Cells
E6-mediated degradation of p53 and other targets via the pro-
teasome is a hallmark of high-risk HPV types and critical to trans-
formation (Chen et al., 2010a; Scheffner et al., 1993), suggesting
that stabilization of E6 targets and consequent pro-apoptotic
signaling may account for the greater sensitivity of HPV-trans-
formed cells to RA190. However, combination of RA190 and bor-
tezomib was synergistic (CI = 0.4) for killing of HeLa cells in vitro,
suggesting distinct targets (Figure S1A). We therefore investi-
gated whether RA190, like bortezomib, could restore the levels
of wild-type p53 in HPV-transformed cervical cancer cells (Lin
et al., 2009). Treatment of HeLa, CaSki, and SiHa cells for
24 hr with RA190 elevated p53 levels as with bortezomib (Fig-
ure 5G, top panel). Rapid and time-dependent recovery of p53
levels was observed within 2 hr of RA190 treatment, reaching
maximal levels by 6 hr (Figure 5G, bottom panel). p53-targets
p21 and Puma (Vousden and Lu, 2002), including their ubiquiti-
nated forms, were also increased in a time-dependent manner
(Figures 5H and S5B). Treatment of HeLa cells with RA190 or
bortezomib increased levels of pro-apoptotic factors targeted
by E6 for degradation (Moody and Laimins, 2010), notably Bax
and Bak (Figure 5H), and the tumor suppressor hDLG-1 in
HeLa (Figure 5H) and CaSki cells (not shown). Thus RA190
stabilizes multiple E6 targets (Moody and Laimins, 2010),
including pro-apoptotic and tumor suppressor proteins, through
proteasome inhibition.ncer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc. 795
(legend on next page)
Cancer Cell
RPN13 Inhibitor RA190 for Cancer Therapy
796 Cancer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc.
Cancer Cell
RPN13 Inhibitor RA190 for Cancer TherapyRA190 Induces Apoptosis and Display of HSP90 on the
Surface of Dying Tumor Cells
The rapid upregulation of pro-apoptotic factors and loss of
viability upon RA190 treatment may reflect apoptosis. Annexin-
V flow cytometric measurements made 12 hr after treating MM
and HeLa cells indicate that RA190 and bortezomib trigger
extensive apoptosis (Figures 6A and 6B). Activation of ICE family
members such as caspase-3 and -7 results in cleavage of poly
ADP ribose polymerase (PARP) to 85 kDa and 25 kDa fragments
and drives apoptosis. The ability of RA190 to trigger caspase-3
activity (Figures 6C and 6D) and PARP cleavage (Figures 6E
and 6F) in MM lines and cervical cancer is consistent with induc-
tion of apoptotic cell death.
Bortezomib treatment of MM cells elevates expression and
surface exposure of HSP90 in association with ‘‘immunogenic’’
cell death (Spisek and Dhodapkar, 2007). RA190 treatment of
HeLa cells for 24 hr produced cell-surface HSP90 on 54.2% of
cells, whereas 12.8% of bortezomib-treated cells and only 3%
of control cells displayed HSP90, demonstrating that this phe-
nomenon is not restricted to MM cells. Notably, cisplatin did
not induce surface display of HSP90, suggesting that not all
types of killing affect cells in this way (Figure 6G). A time course
experiment in HeLa cells demonstrated initiation of surface
HSP90 by 6 hr and strong upregulation by 12 hr following
RA190 treatment (Figure 6G), indicating a similar time course
to Annexin V-staining (not shown), and more rapid onset than
that for bortezomib treatment.
Pharmacokinetics and Safety of RA190
Upon formulation in 20% (w/v) b-hydroxyisopropyl-cyclodextrin
in water, mice were treated with various single oral (p.o.) and
intraperitoneal (i.p.) doses of RA190. With i.p. administration of
10 mg/kg RA190, peak plasma levels (Cmax) were observed in
2 hr, and then declined multi-exponentially with distribution
(T1/2, a) and terminal (T1/2, b) half-lives of 4.2 and 25.5 hr, respec-
tively (Figure S6). After p.o. administration of 20 mg/kg, RA190
plasma concentrations rose rapidly during the first hour and
then declined exponentially with a T1/2, b of 2.6 hr. Based on
the RA190 AUC values, the bioavailability of RA190 delivered
p.o. relative to i.p. was 7.2%. RA190 was detected in kidney
(0.61 mg/g), liver (0.57 mg/g), lung (0.66 mg/g), and spleen
(0.59 mg/g), but not brain 48 hr after the mice were given a single
i.p. dose of 10 mg/kg RA190.
To examine its safety/toxicity profile, mice were given three
doses of 40 mg/kg RA190 p.o. or vehicle alone every third day
andeuthanizedonday12.Bloodwasharvestedandbloodchem-
istry and hematologic analyses performed (Table S2). No signifi-
cant difference between the panels of tests was observed
between the vehicle and RA190-treated groups, except for a
small reduction in triglycerides. The histopathology of the lungs,
kidney, spleen, and liver was unremarkable in both the vehicleFigure 3. RA190 Interacts with the RPN13 Pru Domain
(A and B) Enlarged regions of HSQC spectra for 15N-labeled human RPN13 (A,
orange). Labels for signals affected by RA190 are italicized and bold.
(C) LC-MS experiments for RPN13 Pru domain (top, left) and RA190-exposed RP
(bottom, right). The samples used for these experiments are identical to the one
(D) HSQC spectra of 15N-labeled RPN13 Pru C60,80,121A (black) and after RA190
See also Figure S3.
Caand RA190-treated animals. Similar studies performed in mice
bearingTC-1 tumorsand treatedwith eitherRA190orbortezomib
also suggest that RA190 has apromising safety profile (TableS3).
Proteasome Inhibition In Vivo by RA190
Naked 4UbFL reporter plasmid DNA was delivered either by
gene gun into the skin or in vivo electroporation in muscle (Fig-
ure 7), and the level of luciferase in the mouse was assessed
before and after drug treatment by bioluminescence imaging.
To examine whether RA190 was able to inhibit proteasome func-
tion in vivo, mice (ten per group) were injected i.p. with RA190
(40 mg/kg), bortezomib (1.5 mg/kg), or vehicle 1 day after intra
muscular (i.m.) electroporation with 4UbFL reporter plasmid (Fig-
ure 7A). At 4 hr after treatment, mice treated with RA190 ex-
hibited 4-fold higher levels of bioluminescence compared to
vehicle alone, whereas bortezomib elevated it only 2-fold. One
day posttreatment, both RA190 and bortezomib-treated animals
exhibited a similar 4-fold increase in bioluminescence, suggest-
ing continued inhibition of proteasome function (Figure 7A). The
level of bioluminescence observed in the vehicle-treated mice
decreased steadily over 48 hr, suggesting a slow loss of trans-
fected cells. At 48 hr after RA190 treatment, the mice still show
a significant increase in bioluminescence despite the short
half-life of RA190 in blood (Figure 7A), possibly reflecting slow
regeneration of new proteasomes or the continued presence of
RA190 or active metabolites in tissues. Because papillomavirus
infections are typically restricted to skin and mucosa, the 4UbFL
reporter plasmid was delivered into the skin by gene gun (Best
et al., 2009; Trimble et al., 2003). Similar stabilization of the
4UbFL reporter was observed, albeit of shorter duration, sug-
gesting that both RA190 and bortezomib were also active in
skin (Figure 7B).
Oral administration of RA190 increased the bioluminescence
produced by mice transduced with 4UbFL plasmid either i.m.
by electroporation (Figure 7C) or in skin via gene gun (Figure 7D).
Again, the elevation of bioluminescence in skin was of shorter
duration than that for the i.m. studies, possibly reflecting a
more rapid turnover of skin cells, as compared to transduced
muscle cells of electroporated animals. Topical administration
of RA190 at 4% in Cremophor-EL also stabilized the 4UbFL re-
porter in skin (Figure 7E).
RA190 Treatment Inhibits Tumor Growth in Mice
NOG (NOD/Shi-scid/IL-2Rgnull) mice carrying an NCI-H929 MM
line that expresses luciferase received RA190 or vehicle 20 mg/
kg/day i.p. daily for 7 days. Prior to and at the end of the treat-
ment, mice were imaged for bioluminescence. RA190 showed
potent antitumor activity, even with a 3-day break in the middle
of treatment (Figures 8A and 8B). We have previously described
the susceptibility of human ovarian cancer lines to proteasome
inhibition. Nude mice carrying ES2-luciferase tumor i.p. wereblack) or RPN13 Pru domain (B, black) and after RA190 incubation (A and B,
N13 (top, right), RPN13 Pru domain (bottom, left), and RPN13 Pru C60,80,121A
s used for the corresponding NMR experiments (A, B, and D).
incubation (orange).
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Figure 4. A Surface Opposite RPN13 Ubiquitin-Binding Loops Is
Implicated in RA190 Binding
(A and B) Normalized peak intensity attenuation (D) of RPN13 Pru domain
backbone (A) and side chain (B) amide groups upon binding RA190. The
dashed line indicates one SD above average. Unassigned, overlapping, or
proline groups are excluded from this analysis and indicated (*).
(C) The lowest energy modeled structure for human RPN13 PruRA190 with
RPN13 Pru domain colored according to the data in (A) and (B), such that
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was imagedweekly. Treatment with RA190 significantly inhibited
the ES2 tumor growth (Figures 8C and 8D).
C57BL6 mice carrying HPV16 E6 and E7-transformed and
syngeneic tumor TC-1, which spontaneously induces E7-spe-
cific CD8+ T cell responses, were treated with either RA190
(i.p., 20 mg/kg) or vehicle daily for 7 days and the tumors were
harvested. Tumor lysates probed by western blot for polyubiqui-
tinated proteins were dramatically elevated in the RA190 treat-
ment group, suggesting RA190 can access solid tumor to block
proteasome function (Figure S7A). Oral administration to tumor-
bearing mice of RA190 (40 mg/kg every third day) significantly
inhibited (p < 0.001) TC-1 tumor growth as compared to treat-
ment with vehicle alone (Figure 8E). The final tumor weights after
the 14-day treatment period were 1,873 ± 180 mg in vehicle-
treated mice and 727 ± 101 mg in the RA190-treated mice (p <
0.001). Weight gain and the spontaneous E7-specific CD8+
T cell response did not differ significantly between the vehicle-
and RA190-treated mice (Figure 8F; Figure S7B).
DISCUSSION
Bortezomib improves clinical outcomes for patients with MM or
mantle cell lymphoma, but a significant fraction of tumors are
resistant or become resistant. This has driven efforts to develop
second-generation pharmaceuticals with a distinct mechanism
of proteasome inhibition (Ruschak et al., 2011). The empty
p-orbital on boron of bortezomib accepts electrons from the
hydroxyl group of a key active site threonine to form a pseudoco-
valent bond. Several epoxide or peptide aldehyde proteasome
inhibitors bind to the active site covalently, but the reactivity of
the aldehyde and epoxide groups toward nonspecific targets
and consequent short half-life in vivo are important pharmaco-
logic limitations (Ruschak et al., 2011). Covalent inhibitors typi-
cally contain Michael acceptors that can be more readily modi-
fied structurally to react selectively to target nucleophiles than
highly reactive alkylating agents. The bis-benzylidine piperidone
RA190 is a Michael acceptor that we have engineered over
several iterations and it exhibits specificity against proteasome
ubiquitin receptor RPN13.
We show that RA190 adducts to RPN13 cysteine 88 in the
ubiquitin- and proteasome-binding Pru domain, rather than the
UCH37-interaction domain. Furthermore, we have implicated
residues surrounding C88 as interacting with RA190, and found
evidence of conformational freedom in the docking site.
Although C88 and the surrounding interaction surface of
RPN13 have been implicated in proteasome binding (Chen
et al., 2010b; Schreiner et al., 2008), we were unable to detect
RPN13 displacement from proteasome by RA190. RPN13 binds
sub-stoichiometrically to proteasome (Sakata et al., 2012) and
exists free of proteasome in cells (Hamazaki et al., 2006). In
this free form, its Pru and UCH37-binding domains interact,
which restricts accessibility to the ubiquitin-binding loops and
reduces affinity of RPN13 for ubiquitin 26-fold (Chen et al.,amino acids most affected by RA190 are highlighted in darkest red (see scale
bar for D from A). RA190 carbon, nitrogen, oxygen, and chlorine atoms are
colored light blue, indigo, red, and green, respectively.
See also Figure S4.
Figure 5. RA190 Upregulates UPR and Targets of HPV E6
(A) Immunoblot analysis for ATF-4 and actin in MM.1S cells either untreated (C), or treated with RA190 (190) or bortezomib (Bz) for the indicated times.
(B) Immunoblot analysis for ATF-4 in HeLa cells either untreated (C), or treated with 1 mM of RA190 (190) or 1 mM bortezomib (Bz) for 6 hr.
(C–E) CHOP-10 (C and D) and XBP1s (E) mRNA levels were assessed by quantitative RT-PCR and normalized toGAPDH expression after treating HeLa cells with
1 mM RA190 (190) or 1 mM bortezomib (Bz). Results are expressed as fold change over control-treated cells and represent the average and SD of three inde-
pendent experiments.
(F) Immunoblot analysis for Bax protein levels in MM.1S cells treated as for (A).
(G) Immunoblot analysis for p53 and b-tubulin in the indicated cell line either untreated (C) or treated with 1 mMRA190 (190) or Bortezomib (Bz) for 24 hr (top panel)
or for the indicated times (bottom panel).
(H) After treatment with 1 mMRA190 (190) or 1 mM bortezomib (Bz), HeLa cell lysates were analyzed by immunoblot for p21, Puma, Bax, Bak, and hDLG-1 at the
time points indicated.
See also Figure S5.
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interdomain interaction and thus promote ubiquitin binding
(Chen et al., 2010b). Our results provide evidence that RPN13 in-
terdomain interactions are abrogated by RA190, which couldCatherefore promote more promiscuous interactions between
ubiquitinated proteins and extra-proteasomal RPN13 as well
as interfere with substrate exchange to factors downstream of
RPN13. Future experiments are needed to test this model.ncer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc. 799
Figure 6. RA190 Triggers Apoptosis and Cell Surface Presentation of HSP90
(A and B) HeLa cells treated with 1 mM RA190 (190) or botezomib (Bz) for 12 hr (A) or MM.1S cells treated with 0.5 mM RA190 or bortezomib for 6 hr (B) were
analyzed by flow cytometry after staining with fluorescein-labeled Annexin-V.
(C) HeLa cells treated as in (A) were analyzed by flow cytometry after staining for active caspase-3 and the percent of positive cells ± SD was determined.
(D) A representative flow cytometry analysis of MM.1S cells treated as in (B) and stained for active caspase-3.
(E) Lysates of HeLa cells either untreated (C) or treated with 1 mMRA190 (190) or bortezomib (Bz) after the periods of treatment indicated were immunobloted with
PARP-specific antibody.
(F) MM.1S cells were untreated (C) or treated with 0.5 mM RA190 or botezomib for 6 hr, then lysed for immunoblot analysis with PARP-specific antibody.
(G) HeLa cells were treated with 1 mM RA190, botezomib, or cisplatin and stained at the indicated time points for cell surface HSP90 and analyzed by flow
cytometry.
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Figure 7. Oral, Intraperitoneal, and Topical
Administration of RA190 Inhibits Proteaso-
mal Activity in Mice
(A–E) Mice received 4UbFL DNA delivered either
i.m. by electroporation (A and C), or intradermally
via gene gun (B, D, and E). The transduced mice
were treated with vehicle, RA190, or bortezomib
(ten mice per group) respectively. After the indi-
cated time points of treatment, bioluminescence
wasmeasured by injection of luciferin and imaging
with an IVIS 200 (fold change ± SD, *p < 0.05, **p <
0.01). RA190 was given i.p. (A and B) or orally (C
and D) at 40 mg/kg; bortezomib was given i.p. at
1.5 mg/kg dose (A and B). (E) RA190 was given 4%
in Cremophor-EL topically.
See also Figure S6.
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analogs while keeping the basic benzylidine piperidone skeleton
intact. Substitution of L- for D-phenylalanine or conversion of its
carboxyl moiety to oxime reduced the potency of RA190. Elimi-
nation of Michael acceptor properties by the addition of thiol or
complete removal of the enone moiety nullified drug activity in
cytotoxic and functional assays, demonstrating the importance
of the enone moiety.
Although the IC50 of RA190 is higher than that of the licensed
proteasome inhibitors, oral administration was effective. When
formulated in 20% (w/v) b-hydroxyisopropyl-cyclodextrin in wa-
ter, the oral availability was only approximately 7% that of the i.p.
delivery of RA190. Athough this suggests additional formulation
studies are required for RA190, it proved sufficient for significant
antitumor effects and proteasomal inhibition in vivo. RA190 was
also effective via topical administration at 4% in Cremophor,
suggesting potential for treatment of HPV+ intraepithelial
neoplasia for cancer prevention.
The mechanism of MM killing by licensed proteasome inhibi-
tors via the induction of endoplasmic reticulum stress, UPR,
and p53-independent apoptosis is well documented, and is
also seen in response to RA190. This mechanism is potentially
also active in HPV+ cervical cancer cells, but their relative sensi-Cancer Cell 24, 791–805,tivity to RA190 compared to HPV lines
suggests recovery of E6 targets is a fac-
tor. Indeed, stabilization of p53 is associ-
ated with the expression of downstream
mediators such as p21 and Puma, which
arrest cell cycle progression and promote
apoptosis. However, an siRNA knock-
down study did not support a role for
the recovery of wild-type p53 levels alone
in bortezomib-mediated death of HeLa
cells (Chen et al., 2010a). Thus other E6
targets recovered by RA190, such as
Bak, Bax, and hDLG-1, may act in con-
cert with p53 and UPR to trigger rapid
apoptosis upon RA190 treatment.
Most cell lines of HPV solid tumors
were less sensitive to proteasome inhibi-
tors. However, some of the most rapidly
growing with high rates of protein synthe-sis, including those derived from ovarian and colon cancer, were
similarly sensitive as HPV+ lines. This likely reflects a rapid
buildup of toxic polyubiquitinated protein aggregates seen in
MM, termed aggresomes (Hideshima et al., 2005), stressing the
endoplasmic reticulum and triggering of the UPR (Bazzaro
et al., 2006, 2008). Interestingly, frequent amplification of
RPN13 has been described in both ovarian (Fejzo et al., 2013)
and colon cancer (Chen et al., 2009), suggesting a dependence
upon the proteasome that may confer sensitivity to RA190 and
other proteasome inhibitors.
The side effects of bortezomib and carfilzomib, including neu-
ropathy and thrombocytopenia, remain important clinical con-
cerns (Ruschak et al., 2011). Alternative proteasome inhibitors
with distinct mechanisms of action are potential solutions.
RPN13 is one of two major ubiquitin receptors in the RP (Dever-
aux et al., 1994; Husnjak et al., 2008; Sakata et al., 2012;
Schreiner et al., 2008), and Rpn13 KO mice are viable, suggest-
ing that RA190 may have a favorable toxicity profile (Al-Shami
et al., 2010). Indeed, oral RA190 treatment was well tolerated,
producing no significant difference in hematologic or clinical
chemistry parameters as compared with vehicle, and it did not
affect weight gain or compromise spontaneous antitumor immu-
nity, further suggesting a promising safety profile. Tumor specificDecember 9, 2013 ª2013 Elsevier Inc. 801
Figure 8. RA190 Inhibits Tumor Growth In Vivo
(A) NOGmice carrying NCI-H929-GFP-luc human tumor cells were treated once per day with 20 mg/kg RA190 (i.p.) or vehicle alone (n = 5) on the days indicated.
The mice were imaged before and at the end of the treatment for bioluminescence levels.
(B) Representative bioluminescence images of mice in (A) before (top panel) and after (bottom panel) treatment.
(C) Percentage change of bioluminescence ± SD in nude mice bearing ES2-luciferase tumor cells (tumor cells injected i.p.) receiving 10 mg/kg RA190 (i.p.) or
vehicle alone (n = 8) every day. Prior to and 7 and 14 days after initiation of treatment, the mice were imaged for luciferase activity.
(D) Representative bioluminescence images of mice in (C) before (upper panel) and after (lower panel) treatment.
(E) Mice bearing palpable TC-1 tumors received oral treatment with 40 mg/kg RA190 or vehicle alone (n = 8 per group) every third day. The mean tumor volumes
are plotted ± SD and significant differences indicated (*p < 0.05, **p < 0.01).
(F) After 2 weeks of treatment, the spleens were harvested. The mean number ± SD of IFNg+ CD8+ T cells per 3 3 105 splenocytes elicited with or without E7
peptide stimulation (E7pep) was determined by flow cytometry and plotted.
See also Figure S7 and Tables S2 and S3.
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most chemotherapies are immunosuppressive. That the sponta-
neous E7-specific CD8+ T cell response to TC-1 tumor was not
compromised by RA190 therapy is important given the potential
for such responses to help control HPV+ disease. Indeed, it may
therefore be possible to combine treatment of cervical cancer
with RA190 and therapeutic vaccines targeting HPV E6 and/or
E7 (Welters et al., 2008).
Clinical resistance to bortezomib often develops, and this
has driven further efforts to generate new proteasome inhibi-
tors with distinct chemistry and proteasome targets (Ruschak
et al., 2011). While carfilzomib has a distinct chemistry, it
also targets PSMB5, and resistance has been associated
with PSMB5 mutation and/or overexpression. RA190 was syn-
ergistic with bortezomib for killing of HeLa cells in vitro, sug-
gesting different targets. With a distinct chemistry and target,
RA190 can overcome at least some forms of resistance to bor-
tezomib because its potency remained in two bortezomib-
resistant MM lines. Importantly, while RA190 induces a similar
buildup of polyubiquitinated proteins, the molecular weight of
the accumulated polyubiquitinated proteins was higher than
that for bortezomib. Accumulation of polyubiquitinated pro-
teins, cell surface display of HSP90, and apoptosis occurred
more rapidly upon treatment with RA190 than for bortezomib,
consistent with blockade of the proteasomal recognition of pol-
yubiquitinated proteins and/or trimming of the ubiquitin chains
by the RP.
In conclusion, the ubiquitin receptor RPN13 is a promising
target for cancer treatment. Intriguingly, we note that RPN13
is amplified, overexpressed, and required in both ovarian (Fejzo
et al., 2013) and colon cancer (Chen et al., 2009), suggesting its
importance in cancer biology. Given the issues of drug resis-
tance, route of delivery, and significant side effects of the
licensed proteasome inhibitors, RA190 may be complementary
to, or advantageous over, targeting the 20S proteasome
subunit.
EXPERIMENTAL PROCEDURES
Expanded experimental procedures are provided in the Supplemental Exper-
imental Procedures.
Cell Culture and Reagents
Cell lines were from ATCC and cultured as described elsewhere (Anchoori
et al., 2011). Cell viability was assayed using CellTiter 96 AQueous One Solution
Reagent (Promega). 293TT cells were transfected with RPN13, RPN10
(Origene), UCH37, and HHR23B (Addgene) expression vectors using
TransIT-2020 transfection reagent per Mirus Bio’s instructions. Compounds
were generated using approaches described elsewhere (Anchoori et al.,
2011; Bazzaro et al., 2011).
Quantitative PCR to Measure mRNA Levels
Quantitative PCR was performed per the manufacturer’s instructions (Applied
Biosystems), according to the Livak method and normalized to reference gene
GAPDH.
Flow Cytometry
An annexin V-PE apoptosis detection kit I (BD PharMingen) was used accord-
ing to the manufacturer’s protocol. Cell surface HSP90 was stained with anti-
HSP90 mAb (Stressgen), followed by PE-conjugated anti-mouse IgG1. The
data were acquired with a FACSCalibur and analyzed using CellQuest
software.CaWestern Blots
Antibodies were obtained from commercial sources: anti-ubiquitin, p53
(FL393), p21(WAF1), hDLG-1(2D11), Puma, Bak, Bax, and UCH37 (Cell
Signaling Technology); anti-I-kB-a (C-15), and ATF-4 (SC-200; Santa Cruz
Biotechnology); anti-PARP (BD PharMingen); anti-HSP90 (Stressgen); antitu-
bulin (Sigma); anti-Actin, RPN13, and RPN2 (Sigma-Aldrich); anti-RPN10
and RPN1 (Thermo Scientific); streptavidin Dyna beads and HRP-streptavi-
din (Invitrogen); or peroxidase-linked anti-mouse or rabbit IgG (GE Health-
care UK), and utilized at the concentration recommended by the
manufacturer.
Enzymatic Assays
Reaction mixtures contained 500 nM of the purified 19S RP (R&D Systems) in
19S enzyme assay buffer and 1 mM Ub-AMC. Release of free AMC by the
enzyme reaction was determined by measuring its fluorescence at 380 nm
(excitation) and 440 nm (emission). The 20S proteolytic activity assays were
performed as described elsewhere (Bazzaro et al., 2011).
Biotin Labeling Assay
Human cells (53 106 HeLa or 293TT cells) were lysed using 500 ml mammalian
protein extraction reagent (M-PER; Pierce). Escherichia coli-expressing
RPN13 or L2 (500 ml culture) were harvested by centrifgation and resuspended
in 500 ml BPER (Pierce). Lysates were centrifuged (10,000 3 g, 2 min, 4C) to
remove cell debris. Lysate supernatant (200 ml) was pre-cleared with strepta-
vidin-Dynabeads (20 ml) for 1 hr at 4C, and incubated with compounds at 4C
for 1 hr. Alternatively, pure 19S RP (R&D Systems, E-366; 500 ng) in 20 mM
HEPES, 20 mM NaCl, 1 mM dithiothreitol, and 15% glycerol was incubated
with compounds for 1 hr at room temperature. Samples were boiled in
Laemmli buffer, separated using 4%–15% SDS-PAGE, and transferred to a
PVDF membrane overnight at 4C (24 V). The membrane was blocked with
5%BSA in phosphate-buffered saline with Tween for 1 hr, washed and probed
with HRP-streptavidin (1:10,000 in PBST) for 1 hr at room temperature. After
washing, the blot was developed using HyGLO chemiluminescent detection
reagent (Denville).
Recombinant RPN13 Preparation and NMR
Human RPN13 full-length, RPN13 (1–150), RPN13 (253–407), and His-tagged
UCH37 were prepared as described elsewhere (Chen et al., 2010b; Schreiner
et al., 2008). NMR spectra were acquired at 25C or 10C and at 850 or
900 MHz. RPN13 PruRA190 complexes were generated by HADDOCK 2.1
(Dominguez et al., 2003) and CNS (Bru¨nger et al., 1998). A homology model
of human RPN13 Pru domain was generated by Schro¨dinger based on murine
RPN13 Pru (Protein Data Bank entry 2R2Y) (Schreiner et al., 2008). Ambiguous
interaction restraints were imposed to restrict RPN13 Pru active residues to be
within 2.0 A˚ of any RA190 atom (Dominguez et al., 2003).
Animal Studies
All animal experiments were performed in accordance with protocols
approved by the Animal Care and Use Committee of Johns Hopkins Univer-
sity. Nude, C57BL/6, Balb/c female mice were purchased from the National
Cancer Institute (NCI) and NOG mice were bred in-house. DNA delivery
was via a helium-driven gun (Bio-Rad) as described previously (Trimble
et al., 2003) or electroporation (ElectroSquarePorator 833, BTX-2 Needle
array 5 mm gap, Harvard apparatus) delivered as eight pulses at 106 V for
20 ms with 200 ms intervals. Bioluminescence images were acquired for
10 min with a Xenogen IVIS 200 (Caliper; Luker et al., 2003). C57BL/6 mice
were challenged subcutaneously with 5 3 104 TC-1 cells/mice and E7-spe-
cific CD8+ T cell response and tumor size were measured as described
previously (Trimble et al., 2003). Nude mice were inoculated with 1 3 106
ES2-luciferase cells i.p. in 100 ml PBS. At day 3, mice were imaged for basal
level luciferase activity. NOG mice (five per group) were inoculated with 1 3
106 NCI-H929-GFP-luc cells i.v., and imaged for basal luciferase activity after
4 weeks.
Statistical Analysis
Results are reported as mean ± SD. Statistical significance was calculated us-
ing Prism (V.5 Graphpad) as p% 0.05.ncer Cell 24, 791–805, December 9, 2013 ª2013 Elsevier Inc. 803
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